Taisho Pharmaceutical Holdings Co., Ltd.
TAISF · OTC
12/31/2023 | 9/30/2023 | 6/30/2023 | 3/31/2023 | |
|---|---|---|---|---|
| Market Cap | $684,312,501 | $500,039,643 | $449,455,862 | $452,867,028 |
| - Cash | $246,071,000 | $240,479,000 | $248,189,000 | $255,966,000 |
| + Debt | $8,886,000 | $5,842,000 | $5,770,000 | $2,590,000 |
| Enterprise Value | $447,127,501 | $265,402,643 | $207,036,862 | $199,491,028 |
| Revenue | $83,576,000 | $82,295,000 | $80,802,000 | $73,712,000 |
| % Growth | 1.6% | 1.8% | 9.6% | – |
| Gross Profit | $46,480,000 | $46,915,000 | $48,280,000 | $41,490,000 |
| % Margin | 55.6% | 57% | 59.8% | 56.3% |
| EBITDA | $15,146,000 | $6,729,000 | $13,306,000 | $1,051,000 |
| % Margin | 18.1% | 8.2% | 16.5% | 1.4% |
| Net Income | $2,873,000 | $3,087,000 | $4,363,000 | -$1,902,000 |
| % Margin | 3.4% | 3.8% | 5.4% | -2.6% |
| EPS Diluted | 35 | 37.6 | 53.15 | -23.2 |
| % Growth | -6.9% | -29.3% | 329.1% | – |
| Operating Cash Flow | $21,194,000 | $14,578,000 | $13,904,000 | $13,432,000 |
| Capital Expenditures | $0 | $0 | $0 | $0 |
| Free Cash Flow | $21,194,000 | $14,578,000 | $13,904,000 | $13,432,000 |